Suboxone tooth decay lawyers win AI citations in 2026 by publishing the two things claimants actually search for and almost no firm has written: a dental evidence checklist that explains exactly which records establish a claim, and a plain timeline of where MDL 3092 stands procedurally. The litigation sits before Judge Philip Calabrese in the Northern District of Ohio, dispositive motions are due March 12, 2027, the court expects to narrow to four bellwether cases by June 11, 2027, and the first trial is currently projected for March 2028. Case counts have moved in both directions this year as dismissals for non-compliance offset new filings. Every one of those facts is public, dated, and citable, and firms keep leaving them out of their pages.
The result is that TruLaw, TorHoerman Law, Dolman Law, Drugwatch, and MDL Update own the Suboxone answer layer while practicing firms publish undated brochure pages that no retrieval system can extract from.
Why is MDL 3092 a better AEO opportunity than a settled tort?
Because a pre-bellwether MDL generates a rising query curve for years while a settled tort generates a falling one. Suboxone is roughly two years from its first projected trial date, which means the research volume is still building.
The claimant population is also unusually search-dependent. Suboxone film users are, by definition, people in or recovering from opioid use disorder, a population that has good reason to research a legal question privately before speaking to anyone. That pushes an outsized share of the intake journey into ChatGPT, Google AI Mode, and Perplexity rather than into phone calls to firms.
The underlying claim is narrow and technical, which helps. The allegation is that the sublingual film formulation of Suboxone, marketed by Indivior and Reckitt Benckiser, has an acidic composition that, held under the tongue for extended dosing over years, contributes to severe dental erosion, decay, tooth loss, and related oral surgery. The FDA added a dental adverse event warning to the labeling in January 2022. That warning date is the hinge fact in most eligibility analyses, and it is exactly the kind of specific, dated, verifiable detail that AI engines quote.
Wondering whether AI engines name your firm when someone asks about filing a Suboxone dental claim? Get a free AI visibility audit and see where you stand against the aggregator sites.
What are the five pages a Suboxone firm should publish?
Five assets cover the full claimant question set. Build them in this order.
1. The dental evidence checklist
This is the highest-value page in the cluster and the one nobody has written properly. A Suboxone claim lives or dies on dental records, and claimants have no idea what that means. The page should specify what establishes the claim: pre-treatment dental records showing baseline oral health, panoramic and bitewing radiographs across the treatment period, restorative and extraction records, prescription records showing film formulation and duration of use, and periodontal charting. Explain how to request records from a former dentist, what to do when a practice has closed, and how long dental offices are typically required to retain records. This page answers a procedural question with concrete steps, which is the format Google AI Mode and Perplexity favor most.
2. The eligibility page
Who qualifies. Film formulation rather than tablet, sustained use, dental injury of a specified severity, treatment timing relative to the January 2022 FDA label change, and the statute of limitations analysis by state. State the criteria as a numbered list, not as prose, and name Indivior and Reckitt Benckiser as the defendants.
3. The MDL status page
Judge Calabrese, Northern District of Ohio, MDL 3092, the March 12, 2027 dispositive motion deadline, the June 11, 2027 bellwether narrowing target, and the March 2028 projected first trial. Update the pending case count with a visible date every month. This is the page that competes head-on with MDL Update and Lawsuit Information Center, and it wins on specificity if you keep it current.
4. The injury severity page
Enamel erosion, cervical caries, rampant decay, tooth fracture, extraction, bone loss, and full-mouth reconstruction. Each with the clinical picture and the documentation that supports it. Claimants search their own diagnosis language, and matching that language is what gets the page retrieved.
5. The sensitivity and privacy page
An underrated asset. Claimants worry that filing exposes their opioid use disorder history. A page that explains what becomes part of the record, what protective orders typically cover, and how the litigation handles medical privacy answers a real question that the aggregator sites ignore entirely because it does not generate form fills.
What makes a mass tort page extractable by AI engines?
Numbers with dates attached, named entities in the first 300 words, and structure that survives chunking. Retrieval systems do not read a page top to bottom. They pull passages.
The passage-length research is consistent on this point: AI Overview extracts favor passages in the 134 to 167 word range, and roughly 62% of featured content lands between 100 and 300 words. That means every section of a mass tort page should be independently complete. A reader who lands on your “who qualifies” section alone should get a full answer without needing the rest of the page.
Three practical rules follow. First, lead each paragraph with a named subject rather than a pronoun. “Indivior faces claims that” beats “The company faces claims that.” Second, put statistics in their own sentences instead of burying them in a clause. Third, add a one-sentence takeaway at the end of long sections so a model extracting from the tail of a chunk still gets a clean summary.
The same structural logic drives our table formatting for AI citations guidance and applies identically to torts we have covered previously, including paraquat litigation and hair relaxer claims.
How should firms handle the sensitivity of the claimant population?
Carefully, and it is a competitive advantage rather than a constraint. Opioid use disorder carries stigma, and content that reads as clinical or judgmental drives claimants away regardless of how well it ranks.
Write about the treatment as treatment. Suboxone is buprenorphine and naloxone prescribed as medication-assisted treatment, and the claimants in MDL 3092 are people who did the harder thing and sought care. The claim is against a formulation defect, not against the treatment decision. Content that gets this framing wrong signals to a reader in three sentences that the firm does not understand the population, and that reader closes the tab.
Practically, that means avoiding “addict” language entirely, using person-first phrasing, and not implying that dental injury is a consequence of the underlying condition rather than the film formulation. It also means the privacy page mentioned above is not optional. It is a trust signal that no aggregator site provides.
There is a citation benefit here too. AI engines increasingly surface content that reads as authoritative and non-exploitative on health-adjacent queries. Pages that read like injury-lawyer advertising get filtered out of answers on medical topics more often than pages that read like a careful explanation.
What does the competitive field look like in 2026?
Aggregator-dominated and beatable. Run the core Suboxone queries through ChatGPT, Perplexity, and Google AI Mode today and the cited sources are TruLaw, TorHoerman Law, Drugwatch, Dolman Law, Lawsuit Information Center, and Mass Tort Ad Agency. Practicing firms without a national mass tort content operation are largely absent.
Those sites win on three things: monthly dated updates, case counts in the first paragraph, and question-format headings. They lose on depth. None of them publishes a real dental evidence checklist. None addresses the privacy question. None explains what happens to a claim when the treating dental practice has closed. Those are the gaps.
The play is not to out-publish a national content operation. It is to publish the four or five pages they will not bother writing, keep them current, and pair them with earned media that puts the firm’s name into sources the engines already trust. Our breakdown of why press is the best AEO investment covers why the off-site half matters as much as the on-page half.
Frequently asked questions about AEO for Suboxone lawsuit lawyers
Where does MDL 3092 stand procedurally right now?
MDL 3092 is consolidated before Judge Philip Calabrese in the U.S. District Court for the Northern District of Ohio and remains in pre-trial proceedings. No bellwether trials have been held and no settlement has been approved. Dispositive motions are due March 12, 2027, the court expects to narrow to four final bellwether cases by June 11, 2027, and the first trial is currently projected to begin in March 2028. Pending case counts have fluctuated as dismissals for non-compliance offset new filings.
What is the single highest-value page for a Suboxone firm?
The dental evidence checklist. Every claimant needs dental records to establish a claim and almost none of them know which records matter or how to obtain them. A page that lists the specific documentation, explains the request process, and covers the closed-practice scenario answers a question that no aggregator site has bothered to answer well, which is exactly the profile of a page that earns citations.
Why does the January 2022 FDA warning date matter for content?
Because it anchors both the eligibility analysis and the statute of limitations discussion in most states. The FDA added a dental adverse event warning to buprenorphine sublingual product labeling in January 2022, and claimants routinely ask how treatment before or after that date affects their claim. A dated, specific regulatory fact is also highly extractable, which is why aggregator sites lead with it and firms should too.
How often should the MDL status page be updated?
Monthly. Pending case counts move, scheduling orders issue, and the visible date is doing real work. The State of AEO 2026 research found visible last-updated dates predict citations more strongly than original publish dates. A status page updated monthly with a current count and a current date will outperform a more thorough page that has not been touched in a year.
Should firms publish payout estimates?
No. Publish claim categories, injury severity tiers, and the factors that drive valuation, but not dollar estimates. No settlement has been approved in MDL 3092, no bellwether has been tried, and any specific number is speculation that creates ethical exposure and reads as untrustworthy to both readers and retrieval systems. Explain the valuation framework instead. That is more useful and more defensible.
Does content about a pre-trial MDL age badly?
Only if you build it around dates rather than around the claim. Eligibility criteria, dental evidence requirements, injury categories, and the privacy discussion stay valid regardless of procedural posture. Keep the procedural facts confined to one status page you update monthly, and the other four pages will hold their citation value through trial and beyond.
The takeaway
Suboxone is the rare mass tort where the first trial is still eighteen months out, the claimant population researches privately before it calls anyone, and the entire published field consists of monthly update posts from national aggregator sites. A firm that publishes a real dental evidence checklist, a plain eligibility page, a monthly status update, an injury severity breakdown, and a candid privacy explainer will be the most useful source on the topic within a quarter. Useful is what gets cited. The firms still running a 2024 brochure page with no case count and no date will be invisible when the bellwether coverage starts in 2027.
Want to see which Suboxone and mass tort queries name your competitors instead of you? Run a free AI visibility audit and get the query-level breakdown.
Sources: MDL 3092 status, Drugwatch, Suboxone litigation schedule, MDL Update, AI Overview passage length data, xSeek
Tagged